vs

Side-by-side financial comparison of Enovix Corp (ENVX) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.3M, roughly 1.1× Enovix Corp). Enovix Corp runs the higher net margin — -310.6% vs -1398.3%, a 1087.7% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 15.9%). Enovix Corp produced more free cash flow last quarter ($-28.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 46.2%).

Enovix Corp is an advanced battery technology company that designs, develops and manufactures high-energy-density 3D silicon anode lithium-ion batteries. Its products serve consumer electronics, wearable devices, electric vehicles, and renewable energy storage segments, with customers and operations across North America, Asia and Europe.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

ENVX vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.3M
ENVX
Growing faster (revenue YoY)
RNA
RNA
+418.1% gap
RNA
434.0%
15.9%
ENVX
Higher net margin
ENVX
ENVX
1087.7% more per $
ENVX
-310.6%
-1398.3%
RNA
More free cash flow
ENVX
ENVX
$128.9M more FCF
ENVX
$-28.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
46.2%
ENVX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ENVX
ENVX
RNA
RNA
Revenue
$11.3M
$12.5M
Net Profit
$-35.0M
$-174.4M
Gross Margin
22.2%
Operating Margin
-390.5%
-1513.5%
Net Margin
-310.6%
-1398.3%
Revenue YoY
15.9%
434.0%
Net Profit YoY
6.6%
-117.0%
EPS (diluted)
$-0.14
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENVX
ENVX
RNA
RNA
Q4 25
$11.3M
Q3 25
$8.0M
$12.5M
Q2 25
$7.5M
$3.8M
Q1 25
$5.1M
$1.6M
Q4 24
$9.7M
$3.0M
Q3 24
$4.3M
$2.3M
Q2 24
$3.8M
$2.0M
Q1 24
$5.3M
$3.5M
Net Profit
ENVX
ENVX
RNA
RNA
Q4 25
$-35.0M
Q3 25
$-53.7M
$-174.4M
Q2 25
$-44.5M
$-157.3M
Q1 25
$-23.5M
$-115.8M
Q4 24
$-37.5M
$-102.3M
Q3 24
$-22.5M
$-80.4M
Q2 24
$-115.9M
$-70.8M
Q1 24
$-46.4M
$-68.9M
Gross Margin
ENVX
ENVX
RNA
RNA
Q4 25
22.2%
Q3 25
17.5%
Q2 25
26.0%
Q1 25
5.1%
Q4 24
10.8%
Q3 24
-14.9%
Q2 24
-17.4%
Q1 24
-34.1%
Operating Margin
ENVX
ENVX
RNA
RNA
Q4 25
-390.5%
Q3 25
-587.9%
-1513.5%
Q2 25
-585.6%
-4448.7%
Q1 25
-834.8%
-8360.9%
Q4 24
-355.2%
-4069.6%
Q3 24
-1141.2%
-4200.9%
Q2 24
-2355.4%
-4040.4%
Q1 24
-1330.3%
-2178.6%
Net Margin
ENVX
ENVX
RNA
RNA
Q4 25
-310.6%
Q3 25
-672.3%
-1398.3%
Q2 25
-596.3%
-4089.3%
Q1 25
-461.2%
-7360.0%
Q4 24
-385.6%
-3439.5%
Q3 24
-522.0%
-3441.7%
Q2 24
-3075.2%
-3461.8%
Q1 24
-879.5%
-1943.4%
EPS (diluted)
ENVX
ENVX
RNA
RNA
Q4 25
$-0.14
Q3 25
$-0.27
$-1.27
Q2 25
$-0.22
$-1.21
Q1 25
$-0.12
$-0.90
Q4 24
$0.00
$-0.80
Q3 24
$-0.28
$-0.65
Q2 24
$-0.63
$-0.65
Q1 24
$-0.28
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENVX
ENVX
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$512.0M
$350.2M
Total DebtLower is stronger
$519.5M
Stockholders' EquityBook value
$271.2M
$1.9B
Total Assets
$879.0M
$2.1B
Debt / EquityLower = less leverage
1.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENVX
ENVX
RNA
RNA
Q4 25
$512.0M
Q3 25
$558.8M
$350.2M
Q2 25
$203.4M
$243.9M
Q1 25
$248.2M
$254.2M
Q4 24
$272.9M
$219.9M
Q3 24
$200.9M
$370.2M
Q2 24
$249.9M
$575.8M
Q1 24
$262.4M
$471.4M
Total Debt
ENVX
ENVX
RNA
RNA
Q4 25
$519.5M
Q3 25
$518.6M
Q2 25
$169.7M
Q1 25
$169.4M
Q4 24
$170.0M
Q3 24
$168.9M
Q2 24
$170.1M
Q1 24
$169.8M
Stockholders' Equity
ENVX
ENVX
RNA
RNA
Q4 25
$271.2M
Q3 25
$294.3M
$1.9B
Q2 25
$203.7M
$1.2B
Q1 25
$235.1M
$1.3B
Q4 24
$246.7M
$1.4B
Q3 24
$167.6M
$1.5B
Q2 24
$170.3M
$1.2B
Q1 24
$229.3M
$830.9M
Total Assets
ENVX
ENVX
RNA
RNA
Q4 25
$879.0M
Q3 25
$913.7M
$2.1B
Q2 25
$469.1M
$1.4B
Q1 25
$499.0M
$1.5B
Q4 24
$527.2M
$1.6B
Q3 24
$448.0M
$1.6B
Q2 24
$489.0M
$1.3B
Q1 24
$508.9M
$951.5M
Debt / Equity
ENVX
ENVX
RNA
RNA
Q4 25
1.92×
Q3 25
1.76×
Q2 25
0.83×
Q1 25
0.72×
Q4 24
0.69×
Q3 24
1.01×
Q2 24
1.00×
Q1 24
0.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENVX
ENVX
RNA
RNA
Operating Cash FlowLast quarter
$-27.0M
$-156.2M
Free Cash FlowOCF − Capex
$-28.0M
$-156.9M
FCF MarginFCF / Revenue
-248.6%
-1257.6%
Capex IntensityCapex / Revenue
8.9%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-113.5M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENVX
ENVX
RNA
RNA
Q4 25
$-27.0M
Q3 25
$-25.5M
$-156.2M
Q2 25
$-25.9M
$-199.7M
Q1 25
$-16.9M
$-124.8M
Q4 24
$-16.0M
$-99.9M
Q3 24
$-30.7M
$-65.6M
Q2 24
$-26.9M
$-65.0M
Q1 24
$-35.0M
$-70.4M
Free Cash Flow
ENVX
ENVX
RNA
RNA
Q4 25
$-28.0M
Q3 25
$-28.5M
$-156.9M
Q2 25
$-33.8M
$-203.0M
Q1 25
$-23.2M
$-128.6M
Q4 24
$-32.3M
$-103.8M
Q3 24
$-50.2M
$-67.3M
Q2 24
$-52.2M
$-65.5M
Q1 24
$-50.1M
$-71.3M
FCF Margin
ENVX
ENVX
RNA
RNA
Q4 25
-248.6%
Q3 25
-356.7%
-1257.6%
Q2 25
-453.0%
-5277.1%
Q1 25
-454.7%
-8174.3%
Q4 24
-332.6%
-3491.0%
Q3 24
-1163.2%
-2881.8%
Q2 24
-1384.2%
-3204.6%
Q1 24
-950.9%
-2012.3%
Capex Intensity
ENVX
ENVX
RNA
RNA
Q4 25
8.9%
Q3 25
37.2%
5.7%
Q2 25
106.7%
86.9%
Q1 25
123.0%
238.6%
Q4 24
168.3%
131.7%
Q3 24
452.5%
72.9%
Q2 24
669.0%
26.0%
Q1 24
286.2%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons